The interactions among factors associated with the risk of lung cancer among diabetes patients: a survival tree analysis
“Past epidemiological studies demonstrated mixed findings on the association between diabetes and lung cancer. Given the possible links between diabetes, smoking, and respiratory diseases, this study aims to examine the interaction patterns among factors associated with the risk of lung cancer among diabetes patients.”
Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC
“Osimertinib (Tagrisso) demonstrated a sustained overall survival (OS) benefit, both as a monotherapy treatment and as a backbone for combinations with savolitinib (Orpathys) or datopotamab deruxtecan-dlnk (Datroway), in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to press release from the drug’s developer, AstraZeneca.”
Lexington woman shares lung cancer journey to encourage early screenings
“LEXINGTON, Ky. (LEX 18) — It came out of nowhere for Elizabeth Williams. Life-changing news started with what seemed like a simple cough. “I had a cough in 2019. It just wouldn’t go away. Finally ended up getting a chest x-ray and then a CT scan and a diagnosis in August 2020,” Williams said.”
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI
“Candel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung cancer.”
NCCN 2025: Immune Checkpoint Inhibitors Expand Treatment Options for Early-Stage NSCLC
“Key Takeaways: Neoadjuvant ICIs improve event-free survival and pathological response in NSCLC, with CheckMate816 showing significant benefits in resectable cases. Adjuvant ICI therapy, as seen in IMpower010 and KEYNOTE-091, enhances disease-free survival, particularly in patients with high PD-L1 expression.”
Tobacco Control Helps Avert Millions of Lung Cancer Deaths
“Reductions in smoking prevalence may have helped in averting nearly 4 million deaths related to lung cancer and saved approximately 76 million person-years of life (PYL), according to findings from a study published in CA: A Cancer Journal for Clinicians.”
First-line combination should be ‘new standard’ in advanced lung cancer
“Key takeaways: Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared with osimertinib. The combination also reduced risk for intracranial progression and delayed time to symptomatic progression.”
Increased use of chest X-rays linked to earlier lung cancer diagnosis and improved survival
“A groundbreaking study has revealed a significant link between the frequency of chest X-ray referrals from GPs and earlier diagnosis and improved survival rates for lung cancer patients.”
